From January 2020, Paraná Pharmaceutical Industry will also act in the area of medical prescription.
From January 2020, Paraná´s pharmaceutical industry will also act in the area of medical prescription. This Tuesday (3), Prati-Donaduzzi, Brazil's largest producer of generic drugs doses*, celebrates its 26 anniversary.
By keeping its rapid growth, the pharmaceutical industry based in Toledo (PR) has launched 58 drug presentations this year, totaling 365 treatment options in its portfolio.
The company has invested in process improvement, especially in research, innovation and acquisition of new equipment.
By 2020, Prati will make a new leap in its history. The industry, which began its history in a simple way, will adopt a new market strategy and from January starts to work in the area of medical prescription.
The company will have a portfolio of branded drugs, primarily linked to the Central Nervous System (CNS), designed to treat conditions such as parkinson's, alzheimer's, epilepsy and refractory epilepsy, anxiety, depression and dementia.
According to Eder Fernando Maffissoni, Prati-Donaduzzi CEO, this new stage shows the maturation of the company and concern for the health of Brazilians. “With the entry into the area of prescription, Prati will be present in all sectors of the pharmaceutical market. In public health units, in more than 55 thousand Brazilian pharmacies and now, in its third stage, with doctors”, he explains.
Advertisers
To begin this new phase, the company is assembling a team of advertisers to visit doctors specializing in diseases of the Central Nervous System throughout Brazil. “With this strategy of operation, Prati will occupy a position of relevance into the national pharmaceutical industry. It will strengthen the company's name with the medical profession”, explains Prati-Donaduzzi Medical Prescription Director, Edilson Bianqui.
Other Projects
The pharmaceutical company is prospecting to open a business unit abroad, either in The United States or in Canada. In October this year, Prati-Donaduzzi Group executives visited technology parks, universities and incubators in Miami, Tampa, Gainesville and Orlando in the United States and Montreal in Canada.
“We were looking for a good place to settle down. We want to be present in an ecosystem of innovation. The aim is to license and develop innovative products to be marketed by Prati-Donaduzzi in Brazil and abroad”, said Maffissoni.
For the first time in its history, the company also participated in the CPhI Worldwide - 2019 edition. Considered the largest pharmaceutical exhibition on the planet, the fair took place in November, in Frankfurt, Germany. At the time, Prati presented the active pharmaceutical ingredient, synthetic cannabidiol.
Expansion at sight
The company is also considering building a new factory. Pernambuco Economic Development Agency (AD Diper) offered Prati-Donaduzzi a benefit package for the construction of the new factory in the state of Pernambuco. The Government of Ceará also considered the possibility of the company to build the factory in the state.
Recently, the municipality of São José dos Campos (SP) has presented itself as a strategic place to house a new Prati-Donaduzzi factory. The invitation to take a branch of Paraná industry to the state of Sao Paulo was made by the secretary of Administrative Management and Finance of Sao Jose dos Campos, Jose de Mello Correa, during his visit to the factory in Toledo, Western Paraná.
PRATI-DONADUZZI
Prati-Donaduzzi, the 100% capital Brazilian pharmaceutical industry, is specialized in the development and production of generic drugs. Based in Toledo, western Paraná, Prati-Donaduzzi produces about 11.5 billion therapeutic doses per year and has about 4,300 employees. The company has one of the largest portfolios of generic drugs in Brazil* and aims to grow its sales and production capacity by 15% in 2019.
*IQVIA MAT OUT/2019 PMB + NRC Doses Terapêuticas
